Akoya Biosciences, Inc.
AKYA · NASDAQ
3/31/2025 | 12/31/2024 | 9/30/2024 | 6/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.01 | 0.18 | 0.14 | 0.05 |
| FCF Yield | -10.75% | -3.55% | -7.20% | -10.26% |
| EV / EBITDA | -9.87 | -49.31 | -34.28 | -21.59 |
| Quality | ||||
| ROIC | -15.87% | -5.59% | -7.67% | -9.45% |
| Gross Margin | 59.32% | 67.41% | 62.32% | 57.79% |
| Cash Conversion Ratio | 0.46 | 0.36 | 0.88 | 0.84 |
| Growth | ||||
| Revenue 3-Year CAGR | 0.25% | 2.95% | 7.54% | 13.11% |
| Free Cash Flow Growth | -84.34% | 58.47% | 13.57% | 48.18% |
| Safety | ||||
| Net Debt / EBITDA | -4.72 | -19.20 | -11.98 | -8.84 |
| Interest Coverage | -5.38 | -2.21 | -3.18 | -4.25 |
| Efficiency | ||||
| Inventory Turnover | 0.30 | 0.29 | 0.28 | 0.39 |
| Cash Conversion Cycle | 230.56 | 259.48 | 270.00 | 202.48 |